Researcher-level articles from OncoFirm Diagnostics on cancer biomarkers, early detection evidence and point-of-care oncology testing.
The future of cancer screening is likely to be more risk-stratified, to add blood-based biomarker tests alongside imaging and endoscopy, and to use software to help interpret results. At the…
AI in cancer diagnostics means using machine-learning models to interpret images, assay signals, molecular data or clinical records in support of a decision made by a clinician or laboratory professional….
Tumor antigen detection is the measurement, with antibodies, of proteins or carbohydrate structures that tumors produce or shed into blood and other fluids. In diagnostics it almost always means tumor-associated…
A liquid biopsy is a test on blood or another body fluid that looks for material shed by a tumor: fragments of DNA, whole cells, vesicles or proteins. It gives…
Point-of-care oncology testing means measuring a cancer-related analyte at or near the place where the patient is seen, with the result available in time to inform a decision at the…
Early cancer detection matters because, for most solid tumors, treatment is more likely to be curative while the disease is still localized. It matters most where the health system can…
Cancer biomarkers are measurable characteristics, usually molecules or cells in tissue, blood or other body fluids, that carry information about a cancer: whether it is likely to be present, how…
Affordable early cancer diagnostics are needed because cancer is common everywhere, with GLOBOCAN estimates for 2022 of 20 million new cases and 9.7 million deaths worldwide (Bray et al., 2024),…
Our primary corporate website is now OncoFirm.com.
Visit our main website for the latest information about our cancer diagnostic technologies, research programs, intellectual property, corporate developments, partnerships and investor opportunities.
Continue to OncoFirm.com